论文部分内容阅读
目的:观察研究康艾注射液治疗肺癌的临床效果。方法:选取我科室2014年2月至2015年12月收治疗确诊为肺癌的患者共60例,按随机数字表法分为观察组和对照组各30例,对照组给予紫杉醇+顺铂化疗,观察组在对照组的基础上给予康艾注射液治疗,随访并记录两组患者相关指标变化情况。结果:观察组患者治疗后血清糖类抗原CA125、糖类抗原CA-19-9分别为(284.61±54.19、35.95±14.76)U/ml,均优于对照组(576.49±46.31、50.49±15.41)U/ml(P<0.05)。观察组患者治疗后胸腔积液癌胚抗原CEA、糖分解烯醇酶NSE、细胞角质素片断抗原CYFRA21-1指标分别为(209.75±25.18、42.05±10.47、30.16±9.92)ng/ml,均优于对照组(274.28±28.46、51.35±13.25、42.84±11.32)ng/ml(P<0.05)。观察组患者治疗后血浆中D-二聚体和纤维蛋白原降解产物FDP含量分别为(4.06±1.21、4.87±1.38)mg/L,均优于对照组(5.22±1.27、6.14±2.35)mg/L(P<0.05)。4观察组治疗后消化道反应、骨髓抑制不良反应比例分别为(16.67%、26.67%),低于对照组(30.00%、56.67%)(P<0.05)。5观察组患者治疗后SF-36为(29.6±3.2)分,优于对照组(22.5±3.1)分(P<0.05)。结论:康艾注射液治疗肺癌的临床效果确切,无明显副反应,值得临床进一步研究和应用。
Objective: To observe the clinical effect of Kangai injection in the treatment of lung cancer. Methods: A total of 60 patients diagnosed with lung cancer from February 2014 to December 2015 in our department were selected and divided into observation group (30 cases) and control group (30 cases) by random number table method. The control group was treated with paclitaxel + cisplatin, The observation group was given Kang Ai injection on the basis of the control group, followed up and recorded the changes of the relevant indicators in both groups. Results: After treatment, the levels of serum carbohydrate antigen CA125 and carbohydrate antigen CA-19-9 in the observation group were (284.61 ± 54.19, 35.95 ± 14.76) U / ml, both of which were better than the control group (576.49 ± 46.31 and 50.49 ± 15.41) U / ml (P <0.05). The indexes of CEA, NSE and CYFRA21-1 in pleural effusion were (209.75 ± 25.18, 42.05 ± 10.47, 30.16 ± 9.92) ng / ml in observation group after treatment, respectively (274.28 ± 28.46,51.35 ± 13.25,42.84 ± 11.32) ng / ml in the control group (P <0.05). The plasma levels of D-dimer and fibrinogen FDP in the observation group were (4.06 ± 1.21, 4.87 ± 1.38) mg / L, which were significantly higher than those in the control group (5.22 ± 1.27, 6.14 ± 2.35) mg /L(P<0.05). 4 In the observation group, the rates of gastrointestinal reactions and bone marrow suppression adverse reactions were (16.67%, 26.67%, respectively) lower than those in the control group (30.00%, 56.67%) (P <0.05). SF-36 in the observation group was (29.6 ± 3.2) minutes after treatment, which was better than that in the control group (22.5 ± 3.1) (P <0.05). Conclusion: The clinical effect of Kangai injection in the treatment of lung cancer is exact without obvious side effects, which deserves further clinical research and application.